DWTX — Dogwood Therapeutics Cashflow Statement
0.000.00%
Annual cashflow statement for Dogwood Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16 | -12.2 | -5.3 | -12.3 | -34.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.323 | 0.583 | 0.62 | 4.13 | 18.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.052 | 0.197 | -0.194 | -0.581 | -0.133 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -15.7 | -11.5 | -4.87 | -8.79 | -15.6 |
| Other Investing Cash Flow Items | — | — | — | 3.76 | 0 |
| Sale of Business | |||||
| Cash from Investing Activities | — | — | — | 3.76 | 0 |
| Financing Cash Flow Items | -0.295 | 4.49 | — | 16.7 | 2.95 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.098 | 4.49 | 1.16 | 16.7 | 7.28 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -15.8 | -6.98 | -3.71 | 11.5 | -8.32 |